See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Weijia Liao
Affiliated Hospital of Guilin Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8906-8612
Zhaoquan Huang
Affiliated Hospital of Guilin Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose: Microvascular invasion (MVI) is an independent risk factor for poor prognosis of hepatocellular Carcinoma (HCC), However, there is still a lack of preoperative markers to predict MVI of HCC. This study intends to explore the potential application value of gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) in predicting MVI of HCC, and provide guidance of clinical diagnosis and treatment.
Patients and methods: From March 2010 to December 2015, 230 HCC patients underwent surgical treatment in Affiliated Hospitals of Guilin Medical University were selected. Clinicopathological parameters between MVI group (n = 115) and non-MVI group (n = 115) were comparative analyzed. Gamma-glutamyl transpeptidase (GGT) to lymphocyte count ratio (GLR) was used as the key risk factor of HCC with MVI and its optimal cut-off value was estimated by using the receiver operating characteristic (ROC) curve. Kaplan-meier method was used to analyze the survival of HCC patients, and univariate and multivariate Cox regression analysis were used to establish independent predictors affecting postoperative HCC patients.
Results: The level of GLR in the MVI group and non-MVI group was 84.83 ± 61.84 and 38.42 ± 33.52 (p < 0.001) respectively. According to the ROC curve analysis, the optimal cut-off value of GLR was 56, and the area under ROC curve (AUC) was 0.781 (95%CI, 0.719 - 0.833) for risk prediction in HCC patients with MVI. Multivariate analysis results showed that the tumor size > 5 cm, HCC combined with MVI and GLR > 56 are independent risk factors for poor prognosis of HCC patients. In addition, compared with non-MVI group, patients with MVI had shorter progression-free survival (PFS) rates and overall survival (OS).
Conclusion: GLR could be a predictive biomarker of HCC after operation and a potential predictor of HCC patients combined with MVI.
Keywords
HCC, MVI, GLR, biomarker, prognosis
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 11 Feb, 2020
Editor assigned
On 10 Feb, 2020
Submission checks complete
On 09 Feb, 2020
Editor invited
On 09 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 06 Feb, 2020
Review #3 received
Received 02 Feb, 2020
Editor assigned
On 21 Jan, 2020
Review #2 received
Received 21 Jan, 2020
Reviewers invited
Invitations sent on 21 Jan, 2020
Reviewer #1 agreed
On 21 Jan, 2020
Reviewer #2 agreed
On 21 Jan, 2020
Reviewer #3 agreed
On 21 Jan, 2020
Reviewer #4 agreed
On 21 Jan, 2020
Review #1 received
Received 21 Jan, 2020
Submission checks complete
On 20 Jan, 2020
Editor invited
On 20 Jan, 2020
Version 1
Posted 06 Dec, 2019
No comments provided
Review #2 received
Received 30 Dec, 2019
Editorial decision: Major revision
On 30 Dec, 2019
Review #3 received
Received 26 Dec, 2019
Review #4 received
Received 26 Dec, 2019
Review #1 received
Received 17 Dec, 2019
Reviewer #4 agreed
On 13 Dec, 2019
Reviewer #5 agreed
On 13 Dec, 2019
Reviewer #3 agreed
On 12 Dec, 2019
Reviewer #2 agreed
On 10 Dec, 2019
Reviewer #1 agreed
On 07 Dec, 2019
Editor assigned
On 05 Dec, 2019
Reviewers invited
Invitations sent on 05 Dec, 2019
Submission checks complete
On 04 Dec, 2019
Editor invited
On 02 Dec, 2019
First submitted
On 28 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Weijia Liao
Affiliated Hospital of Guilin Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8906-8612
Zhaoquan Huang
Affiliated Hospital of Guilin Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 11 Feb, 2020
Editor assigned
On 10 Feb, 2020
Submission checks complete
On 09 Feb, 2020
Editor invited
On 09 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 06 Feb, 2020
Review #3 received
Received 02 Feb, 2020
Editor assigned
On 21 Jan, 2020
Review #2 received
Received 21 Jan, 2020
Reviewers invited
Invitations sent on 21 Jan, 2020
Reviewer #1 agreed
On 21 Jan, 2020
Reviewer #2 agreed
On 21 Jan, 2020
Reviewer #3 agreed
On 21 Jan, 2020
Reviewer #4 agreed
On 21 Jan, 2020
Review #1 received
Received 21 Jan, 2020
Submission checks complete
On 20 Jan, 2020
Editor invited
On 20 Jan, 2020
Version 1
Posted 06 Dec, 2019
No comments provided
Review #2 received
Received 30 Dec, 2019
Editorial decision: Major revision
On 30 Dec, 2019
Review #3 received
Received 26 Dec, 2019
Review #4 received
Received 26 Dec, 2019
Review #1 received
Received 17 Dec, 2019
Reviewer #4 agreed
On 13 Dec, 2019
Reviewer #5 agreed
On 13 Dec, 2019
Reviewer #3 agreed
On 12 Dec, 2019
Reviewer #2 agreed
On 10 Dec, 2019
Reviewer #1 agreed
On 07 Dec, 2019
Editor assigned
On 05 Dec, 2019
Reviewers invited
Invitations sent on 05 Dec, 2019
Submission checks complete
On 04 Dec, 2019
Editor invited
On 02 Dec, 2019
First submitted
On 28 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Purpose: Microvascular invasion (MVI) is an independent risk factor for poor prognosis of hepatocellular Carcinoma (HCC), However, there is still a lack of preoperative markers to predict MVI of HCC. This study intends to explore the potential application value of gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) in predicting MVI of HCC, and provide guidance of clinical diagnosis and treatment.
Patients and methods: From March 2010 to December 2015, 230 HCC patients underwent surgical treatment in Affiliated Hospitals of Guilin Medical University were selected. Clinicopathological parameters between MVI group (n = 115) and non-MVI group (n = 115) were comparative analyzed. Gamma-glutamyl transpeptidase (GGT) to lymphocyte count ratio (GLR) was used as the key risk factor of HCC with MVI and its optimal cut-off value was estimated by using the receiver operating characteristic (ROC) curve. Kaplan-meier method was used to analyze the survival of HCC patients, and univariate and multivariate Cox regression analysis were used to establish independent predictors affecting postoperative HCC patients.
Results: The level of GLR in the MVI group and non-MVI group was 84.83 ± 61.84 and 38.42 ± 33.52 (p < 0.001) respectively. According to the ROC curve analysis, the optimal cut-off value of GLR was 56, and the area under ROC curve (AUC) was 0.781 (95%CI, 0.719 - 0.833) for risk prediction in HCC patients with MVI. Multivariate analysis results showed that the tumor size > 5 cm, HCC combined with MVI and GLR > 56 are independent risk factors for poor prognosis of HCC patients. In addition, compared with non-MVI group, patients with MVI had shorter progression-free survival (PFS) rates and overall survival (OS).
Conclusion: GLR could be a predictive biomarker of HCC after operation and a potential predictor of HCC patients combined with MVI.
Figure 1
Figure 2
Figure 3
Loading...